---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-22-000019"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2022-04-27T23:59:59+00:00"
generated_at: "2026-06-26T04:15:26.174345+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amgen Q1 revenues up 6% to $6.2B; Non-GAAP EPS $4.25, +15%; reaffirms 2022 guide

## Summary
- Total revenues $6.2B (+6% YoY); product sales grew 2% with double-digit volume growth for Repatha, Prolia, EVENITY.
- GAAP EPS $2.68 (-5%); Non-GAAP EPS $4.25 (+15%) on revenue growth and lower share count.
- GAAP operating income $2.5B (+17%); Non-GAAP operating margin 54.8% (+3.6 ppts).
- Free cash flow $2.0B vs $1.9B in Q1 2021.
- 2022 guidance: revenue $25.4-26.5B; GAAP EPS $12.53-13.58; Non-GAAP EPS $17-18 reaffirmed.

## SEC filing metadata
- accession: 0000318154-22-000019
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2022-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815422000019/0000318154-22-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815422000019/amgn-20220427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-22-000019
- JSON: https://secwatch.observer/filing/0000318154-22-000019.json
- Plain text: https://secwatch.observer/filing/0000318154-22-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.